Headquartered in Boston, MA·Fiscal year ends December·NASDAQ: AKTS·aktisoncology.com
About Aktis Oncology
Aktis Oncology, Inc. (NASDAQ: AKTS) is a clinical-stage oncology company developing targeted radiopharmaceuticals intended for large patient populations, including tumor types not addressed by existing radiopharmaceutical platforms.
Its proprietary, isotope-agnostic miniprotein radioconjugate platform is designed to deliver radioisotopes such as actinium-225 selectively to tumors. The design aims for high tumor penetration, internalization and retention in cancer cells, with rapid clearance from normal tissue. The platform also allows imaging-based verification of target engagement before therapeutic dosing.
The company has two clinical-stage programs:
- **AKY-1189:** targets Nectin-4 and is in the Phase 1b NECTINIUM-2 trial in urothelial cancer, breast cancer and other Nectin-4-expressing tumors.
- **AKY-2519:** targets B7-H3 and is in the Phase 1b BActinium-1 trial in metastatic castration-resistant prostate cancer and the BActinium-2 trial in non-small cell lung cancer and other B7-H3 tumors.
Two early-stage programs are approaching development-candidate nomination.
Aktis earns collaboration revenue from a discovery partnership with Eli Lilly and Company, which applies the miniprotein platform to novel radioconjugates outside Aktis' proprietary pipeline. For clinical supply, it uses a hybrid model of contract manufacturers, isotope suppliers and an in-house GMP facility at 17 Drydock.
The company completed its IPO in January 2026. Updated
A clinical-stage radiopharmaceutical startup with no product revenue just caught the attention of three of pharma's biggest acquirers, and the rights structure hiding inside its Lilly partnership may explain exactly why.
Alumis, Aktis Oncology, and W.R. Berkley saw the most prominent insider buying of the past week. There were a handful of other notable purchases as well.
Aktis Oncology, Inc. (NASDAQ: AKTS) is a clinical-stage oncology company developing targeted radiopharmaceuticals intended for large patient populations, including tumor types not addressed by existing radiopharmaceutical platforms.
What is the AKTS stock price target?
The Wall Street consensus 12-month price target for AKTS is $35.88.